These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
208 related articles for article (PubMed ID: 37154599)
1. Effectiveness and safety of secondary prevention of non-vitamin K oral anticoagulants use by drug type in Asian patients. Nam KW; Kwon HM; Lee YS; Won SH; Moon HS Int J Stroke; 2023 Oct; 18(8):927-936. PubMed ID: 37154599 [TBL] [Abstract][Full Text] [Related]
2. Outcomes of non-vitamin K oral anticoagulants for secondary prevention in ischemic stroke with atrial fibrillation. Nam KW; Kwon HM; Lee YS; Won SH; Moon HS; Park JH Sci Rep; 2024 Apr; 14(1):9838. PubMed ID: 38684879 [TBL] [Abstract][Full Text] [Related]
3. Effectiveness and Safety of Contemporary Oral Anticoagulants Among Asians With Nonvalvular Atrial Fibrillation. Lee SR; Choi EK; Kwon S; Han KD; Jung JH; Cha MJ; Oh S; Lip GYH Stroke; 2019 Aug; 50(8):2245-2249. PubMed ID: 31208303 [TBL] [Abstract][Full Text] [Related]
4. Effectiveness and Safety of Four Direct Oral Anticoagulants in Asian Patients With Nonvalvular Atrial Fibrillation. Chan YH; Lee HF; See LC; Tu HT; Chao TF; Yeh YH; Wu LS; Kuo CT; Chang SH; Lip GYH Chest; 2019 Sep; 156(3):529-543. PubMed ID: 31103697 [TBL] [Abstract][Full Text] [Related]
5. Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulant and Warfarin in Cirrhotic Patients With Nonvalvular Atrial Fibrillation. Lee HF; Chan YH; Chang SH; Tu HT; Chen SW; Yeh YH; Wu LS; Kuo CF; Kuo CT; See LC J Am Heart Assoc; 2019 Mar; 8(5):e011112. PubMed ID: 30834802 [TBL] [Abstract][Full Text] [Related]
6. The risk of stroke/systemic embolism and major bleeding in Asian patients with non-valvular atrial fibrillation treated with non-vitamin K oral anticoagulants compared to warfarin: Results from a real-world data analysis. Bang OY; On YK; Lee MY; Jang SW; Han S; Han S; Won MM; Park YJ; Lee JM; Choi HY; Kang S; Suh HS; Kim YH PLoS One; 2020; 15(11):e0242922. PubMed ID: 33253294 [TBL] [Abstract][Full Text] [Related]
7. Impact of frailty on the effectiveness and safety of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation: a nationwide cohort study. Grymonprez M; Petrovic M; De Backer TL; Steurbaut S; Lahousse L Eur Heart J Qual Care Clin Outcomes; 2024 Jan; 10(1):55-65. PubMed ID: 36941126 [TBL] [Abstract][Full Text] [Related]
8. Effectiveness and safety of oral anticoagulants in non-valvular atrial fibrillation patients with prior bleeding events: a retrospective analysis of administrative claims databases. Lip GYH; Keshishian A; Kang A; Luo X; Atreja N; Zhang Y; Schuler P; Jiang J; Yuce H; Deitelzweig S J Thromb Thrombolysis; 2022 Jul; 54(1):33-46. PubMed ID: 35579733 [TBL] [Abstract][Full Text] [Related]
9. Comparative effectiveness and safety of direct oral anticoagulants versus vitamin K antagonists in nonvalvular atrial fibrillation: a Canadian multicentre observational cohort study. Durand M; Schnitzer ME; Pang M; Carney G; Eltonsy S; Filion KB; Fisher A; Jun M; Kuo IF; Renoux C; Paterson JM; Quail J; Matteau A; CMAJ Open; 2020; 8(4):E877-E886. PubMed ID: 33355273 [TBL] [Abstract][Full Text] [Related]
10. Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients. Lip GYH; Keshishian A; Li X; Hamilton M; Masseria C; Gupta K; Luo X; Mardekian J; Friend K; Nadkarni A; Pan X; Baser O; Deitelzweig S Stroke; 2018 Dec; 49(12):2933-2944. PubMed ID: 30571400 [TBL] [Abstract][Full Text] [Related]
11. Drug Utilization Pattern of Oral Anticoagulants in Patients with Atrial Fibrillation: A Nationwide Population-Based Study in Korea. Lee MY; Han S; Bang OY; On YK; Jang SW; Han S; Ryu J; Park YJ; Kang S; Suh HS; Kim YH Adv Ther; 2022 Jul; 39(7):3112-3130. PubMed ID: 35524839 [TBL] [Abstract][Full Text] [Related]
12. Comparative Stroke, Bleeding, and Mortality Risks in Older Medicare Patients Treated with Oral Anticoagulants for Nonvalvular Atrial Fibrillation. Graham DJ; Baro E; Zhang R; Liao J; Wernecke M; Reichman ME; Hu M; Illoh O; Wei Y; Goulding MR; Chillarige Y; Southworth MR; MaCurdy TE; Kelman JA Am J Med; 2019 May; 132(5):596-604.e11. PubMed ID: 30639551 [TBL] [Abstract][Full Text] [Related]
13. Real-World Comparative Effectiveness, Safety, and Health Care Costs of Oral Anticoagulants in Nonvalvular Atrial Fibrillation Patients in the U.S. Department of Defense Population. Gupta K; Trocio J; Keshishian A; Zhang Q; Dina O; Mardekian J; Rosenblatt L; Liu X; Hede S; Nadkarni A; Shank T J Manag Care Spec Pharm; 2018 Nov; 24(11):1116-1127. PubMed ID: 30212268 [TBL] [Abstract][Full Text] [Related]
14. Clinical outcomes in elderly atrial fibrillation patients at increased bleeding risk treated with very low dose vs. regular-dose non-vitamin K antagonist oral anticoagulants: a nationwide cohort study. Chan YH; Chao TF; Chen SW; Lee HF; Li PR; Yeh YH; Kuo CT; See LC; Lip GYH Eur Heart J Cardiovasc Pharmacother; 2023 Dec; 9(8):681-691. PubMed ID: 37580139 [TBL] [Abstract][Full Text] [Related]
15. Comparisons between Oral Anticoagulants among Older Nonvalvular Atrial Fibrillation Patients. Deitelzweig S; Keshishian A; Li X; Kang A; Dhamane AD; Luo X; Balachander N; Rosenblatt L; Mardekian J; Pan X; Nadkarni A; Di Fusco M; Garcia Reeves AB; Yuce H; Lip GYH J Am Geriatr Soc; 2019 Aug; 67(8):1662-1671. PubMed ID: 31112292 [TBL] [Abstract][Full Text] [Related]
16. Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Asian Patients With Atrial Fibrillation. Cha MJ; Choi EK; Han KD; Lee SR; Lim WH; Oh S; Lip GYH Stroke; 2017 Nov; 48(11):3040-3048. PubMed ID: 28974629 [TBL] [Abstract][Full Text] [Related]
17. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses. Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628 [TBL] [Abstract][Full Text] [Related]
18. Effectiveness and Safety of Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation and Diabetes Mellitus. Lip GYH; Keshishian AV; Kang AL; Li X; Dhamane AD; Luo X; Balachander N; Rosenblatt L; Mardekian J; Nadkarni A; Pan X; Di Fusco M; Garcia Reeves AB; Yuce H; Deitelzweig SB Mayo Clin Proc; 2020 May; 95(5):929-943. PubMed ID: 32370854 [TBL] [Abstract][Full Text] [Related]
19. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study. Maura G; Blotière PO; Bouillon K; Billionnet C; Ricordeau P; Alla F; Zureik M Circulation; 2015 Sep; 132(13):1252-60. PubMed ID: 26199338 [TBL] [Abstract][Full Text] [Related]
20. Thromboembolic, Bleeding, and Mortality Risks of Rivaroxaban and Dabigatran in Asians With Nonvalvular Atrial Fibrillation. Chan YH; Kuo CT; Yeh YH; Chang SH; Wu LS; Lee HF; Tu HT; See LC J Am Coll Cardiol; 2016 Sep; 68(13):1389-1401. PubMed ID: 27659460 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]